Company Filing History:
Years Active: 1991-2001
Title: The Innovations of Hema Pande in Cytomegalovirus Research
Introduction
Hema Pande, an esteemed inventor based in Arcadia, CA, has made significant contributions to the field of virology, particularly regarding human cytomegalovirus (HCMV). With a remarkable portfolio that includes four patents, she is recognized for her innovative approaches to diagnosing and preventing HCMV infections.
Latest Patents
Among her notable inventions, Hema's most recent patents include:
1. **Method for Detection and Prevention of Human Cytomegalovirus Infection** - This patent discloses amino acid sequences of the late 64 kilodalton protein of human cytomegalovirus (HCMVgp64), which are instrumental in diagnosing and preventing HCMV infections.
2. **Induction of Cytolytic T-Lymphocytes with Cytomegalovirus Polypeptides** - This innovation presents immunogens useful for HCMV vaccines or skin tests, which incorporate human cytomegalovirus matrix proteins or their fractions. It further identifies these matrix proteins as target antigens for cytotoxic T-lymphocytes specific to HCMV.
Career Highlights
Hema Pande currently works at City of Hope, a prominent research and treatment center. Her work focuses on developing solutions that enhance immune responses against viral infections, showcasing her dedication to advancing medical science.
Collaborations
Throughout her career, Hema has collaborated with other distinguished experts, including John A. Zaia and Arthur D. Riggs. These partnerships have facilitated significant advancements in HCMV research and therapeutic strategies.
Conclusion
Hema Pande's innovative work in the detection and prevention of human cytomegalovirus is a testament to her commitment to improving public health through scientific discovery. Her contributions continue to impact the field and inspire future research efforts against viral infections.